Technical Analysis for AGTC - Applied Genetic Technologies Corporation

Grade Last Price % Change Price Change
F 3.8827 0.07% 0.00
AGTC closed up 5.72 percent on Friday, May 14, 2021, on 69 percent of normal volume. The stock exhibited some range contraction during this trading session as price made an NR7 -- narrowest range of the last seven sessions.

Trend Table & Recent EOD Signals

ADX Long Term Intermediate Term Short Term
Weak or Absent Down Down Up
Historical AGTC trend table...

Date Alert Name Type % Chg
Stochastic Buy Signal Bullish 0.07%
NR7 Range Contraction 0.07%
Oversold Stochastic Weakness 0.07%
New 52 Week Low Weakness 5.80%
Oversold Stochastic Weakness 5.80%
Shooting Star Candlestick Bearish 3.26%
Doji - Bearish? Reversal 3.26%
Stochastic Reached Oversold Weakness 3.26%
Oversold Stochastic Weakness 3.26%
Inside Day Range Contraction -0.19%
Older End-of-Day Signals for AGTC ...

   Recent Intraday Alerts -- Get these alerts pushed to you via our Mobile App

Alert Time
Possible NR7 about 2 hours ago
60 Minute Opening Range Breakdown about 2 hours ago
Down 2 % about 2 hours ago
10 DMA Support about 6 hours ago
Rose Above Previous Day's High about 6 hours ago
View Earlier Intraday Alerts

Get this analysis on your stocks daily!

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.

Profile

Applied Genetic Technologies Corporation Description

Applied Genetic Technologies Corporation, a clinical-stage biotechnology company, develops gene therapy products for inherited orphan ophthalmology diseases in the United States. Its lead product candidates in the preclinical stage include treatments for X-linked retinoschisis, Achromatopsia, and X-linked retinitis pigmentosa, which are diseases of the eye caused by mutations in single genes. The company also completed preclinical proof-of-concept studies, and Phase I and Phase II clinical trials of a treatment for alpha-1 antitrypsin deficiency, an inherited orphan lung disease. In addition, it has proof-of-concept programs for other eye diseases, such as leber congenital amaurosis (type 2), and wet form of age-related macular degeneration. Applied Genetic Technologies Corporation was founded in 1999 and is headquartered in Alachua, Florida.


Classification

Sector: Healthcare
Industry: Biotechnology
Keywords: Biotechnology Diseases Eye Gene Therapy Macular Degeneration Ophthalmology Related Macular Degeneration Eye Disease Vision Age Related Macular Degeneration Antitrypsin Deficiency Retinitis Eye Diseases Retinitis Pigmentosa Gene Therapy Products Retinoschisis X Linked Retinitis Pigmentosa

Is AGTC a Buy, Sell or Hold?

Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength

Indicators

Indicator Value
52 Week High 9.66
52 Week Low 3.53
Average Volume 1,415,941
200-Day Moving Average 4.96
50-Day Moving Average 4.58
20-Day Moving Average 3.96
10-Day Moving Average 3.83
Average True Range 0.31
ADX 21.72
+DI 15.35
-DI 26.22
Chandelier Exit (Long, 3 ATRs ) 3.50
Chandelier Exit (Short, 3 ATRs ) 4.46
Upper Bollinger Band 4.39
Lower Bollinger Band 3.52
Percent B (%b) 0.41
BandWidth 22.17
MACD Line -0.22
MACD Signal Line -0.24
MACD Histogram 0.0176
Fundamentals Value
Market Cap 100.45 Million
Num Shares 25.9 Million
EPS -0.11
Price-to-Earnings (P/E) Ratio -35.27
Price-to-Sales 43.79
Price-to-Book 2.15
PEG Ratio 0.00
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 4.18
Resistance 3 (R3) 4.15 4.03 4.13
Resistance 2 (R2) 4.03 3.95 4.04 4.11
Resistance 1 (R1) 3.95 3.90 3.99 3.98 4.10
Pivot Point 3.83 3.83 3.85 3.84 3.83
Support 1 (S1) 3.75 3.75 3.79 3.78 3.66
Support 2 (S2) 3.63 3.70 3.64 3.65
Support 3 (S3) 3.55 3.63 3.63
Support 4 (S4) 3.58